GLP-1s Before Egg Retrieval or Embryo Transfer

Retrieval and transfer need separate medication decisions

Tell your fertility team and GLP-1 prescriber before ovarian stimulation or a planned transfer. Egg retrieval raises procedure and anesthesia questions; embryo transfer raises pregnancy-exposure questions. One stop date cannot be assumed to answer both. Your team needs the exact medicine, treatment stage, symptoms and fertility schedule before giving instructions.

This matters when a cycle has already required appointments, childcare, money and time away from work. The goal is to identify a conflict while there is still room to resolve it. Do not wait until the preprocedure nurse asks about your last injection to mention a medicine prescribed by another office.

A medication review is also separate from a clinic's eligibility policy. ASRM's obesity and reproduction guidance discusses procedural capability, anesthesia safety and the consequences of delaying fertility care. It does not endorse a society-wide BMI cutoff or establish that preconception weight loss improves every fertility outcome¹.

Start by naming the next step in treatment

A person freezing eggs, a person having a freeze-all IVF cycle and a person preparing for a fresh transfer may have very different immediate pregnancy plans. Tell the clinician which situation applies. The phrase “I am doing IVF” does not describe the entire exposure timeline.

The table is a conversation map, not permission to continue treatment through any stage. Your fertility specialist may have reasons to adjust the schedule that do not apply to someone else's cycle. Ask what the recommendation is intended to prevent and which clinician will make the final decision.

Why the retrieval team asks about stomach symptoms

GLP-1 medicines can delay stomach emptying. During general anesthesia or deep sedation, retained stomach contents can create an aspiration concern. Current ASA patient guidance describes an individualized assessment rather than a universal instruction that every patient must stop the same number of days beforehand².

Recent dose increases, significant gastrointestinal symptoms and other conditions affecting gastric emptying can influence that assessment. The multisociety guidance also weighs consequences of interruption, including glucose management for people with diabetes³. A standard fasting handout does not resolve every medication question.

Our guide to GLP-1s before surgery or colonoscopy explains the wider anesthesia issue. For retrieval, add the fertility timeline: the procedure date may be tied closely to the stimulation cycle. If instructions change late, ask the fertility and anesthesia teams to speak directly rather than leaving you to choose between their messages.

Donald E. Arnold, then ASA president, emphasized advance assessment of dose increases and stomach symptoms in comments published in the American Society of Anesthesiologists’ guidance announcement³. His point was to resolve foreseeable risks before the procedure, rather than discover them on the day. For someone organizing retrieval around childcare and work, that is a practical reason to request the anesthesia review early. It is professional advice about procedural planning, not evidence that continuing a GLP-1 improves fertility outcomes.

A medication hold for anesthesia is not a pregnancy washout

The U.S. Wegovy prescribing information advises stopping at least two months before a planned pregnancy for weight reduction or cardiovascular-risk reduction. That is a product-specific reproductive precaution, not a universal two-month rule for every GLP-1 procedure⁵. It cannot be replaced by a shorter anesthesia instruction simply because retrieval has been completed.

The current U.S. Zepbound label advises discontinuation when pregnancy is recognized and discussion of pregnancy intentions, but does not give the same fixed two-month preconception instruction⁶. Do not create a tirzepatide transfer interval by copying the Wegovy rule or by counting drug half-lives yourself. The fertility specialist and prescriber should agree on the product-specific plan.

Internet advice may also come from another jurisdiction. UK professional recommendations and product information can describe preconception intervals differently from U.S. labeling. Bring the source to your clinician if it conflicts with their instructions. The underlying question is which guidance applies to your actual prescription and intended pregnancy, not which online number appears most often.

Our trying-to-conceive guide covers that broader planning discussion. Here the essential distinction is that retrieving eggs and placing an embryo are different milestones. A clear plan names both rather than referring vaguely to “before IVF.”

Do not assume every transfer uses the retrieval anesthesia plan

ASRM's embryo-transfer guideline does not recommend routine anesthesia merely to improve transfer outcomes⁴. That does not tell us what your particular clinic plans, or whether another procedure is scheduled at the same visit. Ask rather than assuming that all fertility appointments involve sedation, or that none do.

A frozen transfer without the same anesthesia exposure can still involve an intended pregnancy. Conversely, egg freezing without an immediate transfer can still require anesthesia assessment. The reproductive and procedural questions remain independent even when the same clinic handles them both.

Give the team the names of all prescribed hormones, diabetes medicines, supplements and over-the-counter products. If the fertility office changes the procedure or transfer plan, tell the GLP-1 prescriber. A medication decision made for an earlier schedule may need reconsideration when the next step changes.

Avoid turning weight loss into a promised fertility treatment

A lower weight or improved metabolic health can be useful for some patients. It does not establish that a GLP-1 improves egg quality, embryo quality or live-birth chances for every woman. Fertility outcomes vary with age, diagnosis, treatment and other factors, and the existing general guidance does not turn a weight-management prescription into a fertility indication¹.

Ask how a proposed delay balances the clinic's procedural capability, your medical risks and your reproductive timeline. A policy at one ambulatory center is not proof that every center has identical equipment, anesthesia resources or eligibility criteria. Your team should explain the reason for its recommendation without promising an outcome the evidence cannot establish.

The same care applies to conception between appointments. If pregnancy is possible before the planned transfer, discuss contraception. Our birth-control guide explains why the tirzepatide pill warning can matter while someone is still preparing for treatment. A fertility plan does not automatically prevent an unplanned exposure.

Leave room for the recovery and restart decision

If treatment is interrupted, obtain a restart plan from the prescribing clinician. Ask how recovery, eating and drinking, symptoms and the length of the gap affect the next dose. The instructions may differ from simply taking the missed injection after the procedure. Our missed-dose and restarting guide explains why product-specific rules matter.

Before the cycle begins, aim to know who reviews the last dose, who decides about anesthesia, who coordinates pregnancy exposure and whom to contact if the schedule changes. Keep that information alongside the fertility calendar. You should not have to reconstruct responsibility from several portal conversations on the morning of retrieval.

Urgent care should not wait while you solve a medication timetable. For planned care, however, separating the procedure, pregnancy and restart decisions makes the next conversation much clearer—and reduces the chance of discovering an unresolved question after a cycle is already underway.